Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Non-Current Deffered Revenue (2022 - 2023)

Historic Non-Current Deffered Revenue for Capricor Therapeutics (CAPR) over the last 4 years, with Q3 2023 value amounting to $953470.0.

  • Capricor Therapeutics' Non-Current Deffered Revenue fell 9031.81% to $953470.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $953470.0, marking a year-over-year decrease of 9031.81%. This contributed to the annual value of $9.5 million for FY2022, which is N/A changed from last year.
  • Latest data reveals that Capricor Therapeutics reported Non-Current Deffered Revenue of $953470.0 as of Q3 2023, which was down 9031.81% from $3.2 million recorded in Q2 2023.
  • In the past 5 years, Capricor Therapeutics' Non-Current Deffered Revenue ranged from a high of $20.3 million in Q1 2022 and a low of $953470.0 during Q3 2023